louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00769535: Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma
Official title: Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatocellular Carcinoma
Keywords: heat shock protein70
tumor necrosis factor-alpha promoter
polymorphism
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2008-10-09
Enrollment: 600
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Polymorphisms of HSP70 and tumor necrosis factor-alpha promoter in patients with hepatocellular carcinoma, chronic liver disease and healthy controls will be measured by PCR-RFLP or direct sequencing. The clinical relevance of patients will be compared in those with polymorphism and those without.

Detailed description: Heat shock protein 70 (HSP 70) may be involved in various aspects of immune system including infection, autoimmunity, and tumor immunity. The relationship between HSP70 expression, disease activity and cancer prognosis varied according to type of cancer. The overexpression of HSP70 by tumor cells contributes to tumor behavior. HSP70 is present in normal and abnormal hepatocytes, and was reported to be over-expressed in both hepatoma cell lines and human hepatocellular carcinoma (HCC) tissue. Recent study indicated that HSP70 is a molecular marker during early hepatocarcinogenesis. It is also involved in anti-tumor immunity in HCC.We also investigate the polymorphism of tumor necrosis factor-alpha promoter, and correlated to clinical relevance.

Eligibility criteria: Inclusion Criteria:

* History proven HCC patients

Exclusion Criteria:

* No-definite diagnosed patients

Primary outcomes:
measure: Clinical relevance
timeFrame: year
Secondary outcomes:
measure: Clinical relevance
timeFrame: year
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University
state: Kaohsiun
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University
Study officials:
affiliation: Professor of Medicine
name: Jung-Fa Tsai, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03411135: Vitiligo Extent Score (VES) Score in Comparison to Vitiligo Area and Severity Index (VASI) Score
Official title: In-depth Analysis of the Implementation of Vitiligo Extent Score (VES) Score in Comparison to Vitiligo Area and Severity Index (VASI) Score
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Vitiligo
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-01-26
Enrollment: 101
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Vitiligo patients presenting to dermatology outpatient clinic at Kasr Alainy Teaching Hospital.

Brief summary: All patients with vitiligo attending dermatology outpatient clinic at Kasr Alainy Teaching Hospital will be enrolled in this study to compare VES and VASI scores and evaluate them as assessment methods


Eligibility criteria: Inclusion Criteria:

* Age \> 18.
* Non-segmental vitiligo patients

Exclusion Criteria:

* Age \< 18
* Segmental vitiligo

Primary outcomes:
measure: The evaluation of the use of vitiligo extent score (VES) as a scoring system for vitiligo
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06458335: Intervening on Opioid Use and Loneliness
Official title: Addressing Loneliness as a Therapy Target Among Individuals Using Opioids
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Opioid Use Disorder
Loneliness
Social Isolation
Lead sponsor: University of Rochester
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
name: Medical University of South Carolina
name: Ohio State University
First posted: 2024-06-13
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to enroll 300 participants who will be assigned to one of three 3 groups. Each group will receive an intervention lasting 6, weekly sessions of 40-60 minutes. Eligibility include having an opioid use disorder and reporting loneliness or feeling alone or disconnected.

Detailed description: Individuals (n = 300) with an opioid use disorder reporting loneliness will be randomized to either (1) therapist-delivered cognitive-behavioral therapy for perceived social isolation, (2) therapist-delivered Health Education, or (3) self-guided Health Education. Loneliness, opioid and other substance use, the amount of social interactions, social support, and mental and physical health factors prior to starting the treatment, after completing the treatment, and 1, 3, and 6 months following the treatment will be assessed to see how well they work compared to each other.

Eligibility criteria: Inclusion Criteria:

* Must be 18+
* understand English -have internet access-
* screen positive for an opioid use disorder
* screen positive for elevated loneliness

Exclusion Criteria:

* does not understand consent
* does not have consistent access to a phone and internet

Primary outcomes:
measure: Mean change in loneliness
timeFrame: Baseline to 6 months
measure: Mean change in number of days of opioid use
timeFrame: Baseline to 6 months
Secondary outcomes:
measure: mean change in social interactions
timeFrame: Baseline to 6 months
measure: Mean change in depression
timeFrame: Baseline to 6 months
measure: Mean change in anxiety
timeFrame: Baseline to 6 months
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester
state: New York
Study officials:
References:
Clinical trial NCT00764335: Unilateral vs Bilateral Total Hip Arthroplasty
Official title: Unilateral vs Bilateral Total Hip Arthroplasty - the Influence of Medial Femoral Head Offset and Effects on Strength and Aerobic Endurance Capacity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoarthritis, Hip
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: OrtoMedic A/S, Oslo
name: Scandinavian Customized Prosthesis (SCP)
First posted: 2008-10-02
Enrollment: 40
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects selected from orthopaedic out-patient department

Brief summary: The purpose of the present study was to determine whether unilaterally operated total hip arthroplasty (THA) patients were superior to bilaterally operated THA patients with respect to aerobic endurance capacity, muscle strength and gait patterns 3-5 years after surgery, and to what extent medial femoral head offset (FO) influenced hip abductor strength.


Eligibility criteria: Inclusion Criteria:

* Undergone hip surgery 3-5 years ago
* Age \< 70 years

Exclusion Criteria:

* Heart or lung diseases
* Malign diseases
* No muscle/skeletal diseases that compromises testing

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Norwegian University of Science and Technology
name: Jan Hoff, PhD prof
role: STUDY_DIRECTOR
References:
citation: Husby VS, Bjorgen S, Hoff J, Helgerud J, Benum P, Husby OS. Unilateral vs. bilateral total hip arthroplasty - the influence of medial femoral head offset and effects on strength and aerobic endurance capacity. Hip Int. 2010 Apr-Jun;20(2):204-14. doi: 10.1177/112070001002000211.
Clinical trial NCT01301235: Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics in Patients With Mitochondrial Myopathy
Official title: Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics of the Vastus Lateralis After Sub-maximal Exercise in Patients With Mitochondrial Myopathy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mitochondrial Disease
Keywords: Mitochondria
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2011-02-23
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with mitochondrial disease

Brief summary: This is a developmental protocol to determine the MRI based 31P-MRS changes seen in subjects with mitochondrial myopathy using our dynamic exercise protocol and to identify the ideal variable(s) to represent mitochondrial function.


Eligibility criteria: Inclusion Criteria:

1. Men and women ≥ age 18 years old with primary mitochondrial myopathy
2. Known alteration in electron transport chain activity (\<25 % activity of ETC) or known mutations in mitochondrial gene.

Exclusion Criteria:

Failure based on standard clinical MRI Screening form - the form is intended to establish the safety of subjects participating in the MRI scan without divulging any confidentiality information -

Primary outcomes:
measure: PCr recovery after submaximal exercise by 31P-MRS
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
References:
Clinical trial NCT00757835: 24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG
Official title: 24-hour IOP Control With the Travoprost/Timolol Fixed Combination Compared With the Latanoprost/Timolol Fixed Combination, When Both Are Dosed in the Evening in Patients With Exfoliative Glaucoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Glaucoma
Keywords: 24-hour IOP
exfoliative glaucoma
travoprost/timolol
latanoprost/timolol
fixed combinations
Lead sponsor: Aristotle University Of Thessaloniki
Sponsor class: OTHER
Collaborators: name: Alcon Research
First posted: 2008-09-23
Enrollment: 40
Sex: ALL
Minimum age (years): 21
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: A crossover, randomized, single-masked study which compares the short-term (3 months) 24-hour IOP control and safety of travoprost/timolol fixed combination given once in the evening, versus that of latanoprost/timolol fixed combination given once in the evening in patients with exfoliative glaucoma. The primary objective of this trial is to compare the quality of 24-hour IOP control after 3 months of chronic therapy with these two medications.


Eligibility criteria: Inclusion Criteria:

* Patient has XFG and is older than 29 years
* The IOP without treatment is greater than 25 mm Hg and lower than 40 mm Hg at baseline (2 readings at 10:00)
* Patient can be safely washed out without risk for significant deterioration
* Distance best corrected Snelen visual acuity better than 0.1
* No contraindication to prostaglandins or β-blockers
* No history of lack of response (\<10% reduction) to any medication
* Patient can understand the instructions and comply to medications
* Open normal appearing angles
* No sign of ocular infection, except blepharitis, corneal abnormality that may affect IOP measurements etc

Exclusion Criteria:

* History of trauma, inflammation, surgery, past use of steroids (within 2 months), severe dry eyes and use of contact lenses
* Patient is a female of childbearing potential or lactating mother

Primary outcomes:
measure: Travoprost/timolol fixed combination will demonstrate better quality of 24-hour IOP control than latanoprost/timolol
timeFrame: 3 months
Secondary outcomes:
measure: Incidence of side effects with the two medications
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
affiliation: Glaucoma Unit, 1st University Department of Ophthalmology
name: Anastasios G Konstas, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05453435: Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)
Official title: Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) (REHEB)：a Single Arm, Open Label, Multi-center Phase II Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Resolved Hepatitis B
CD20 Positive B-cell Lymphoma
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2022-07-12
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase 2 trial aims to evaluate the efficacy of entecavir prophylacxis for hepatitis B virus (HBV) reactivation that continues until 6 months after completing CD20 monoclonal antibody therapy in patients with CD20-positive B-cell lymphomas and resolved hepatitis B (negative hepatitis B surface antigen, positive hepatitis B core antibody).


Eligibility criteria: Inclusion Criteria:

* Histopathologically confirmed CD20 positive B-cell lymphoma;
* Plan to receive first-line anti-lymphoma therapy containing CD20 monoclonal antibodies;
* Negative HBsAg, HBV-DNA lower than the detection limit and positive anti-HBC at baseline;
* Total bilirubin less than 1.5X the upper limit of normal (ULN), AST and ALT less than 2.5X ULN;
* ECOG PS: 0\~2;
* Estimated survival time \>3 months.

Exclusion Criteria:

* Positive HBsAg or HBV-DNA higher than the detection limit at baseline;
* Previous chemotherapy or radiotherapy for lymphoma;
* Other primary liver diseases, such as chronic hepatitis C, hepatitis D, autoimmune hepatitis, Wilson' s disease or primary biliary cirrhosis;
* Pregnant or lactating women;
* History of immunodeficiency, including positive HIV, or other acquired congenital immunodeficiency disease, or history of organ transplantation.

Primary outcomes:
measure: Cumulative HBV reactivation rate
timeFrame: 12 months
Secondary outcomes:
measure: Incidence of HBV-related liver failure
timeFrame: 12 months
measure: Incidence of HBV-related chemotherapy disruption
timeFrame: 12 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
state: State...
Study officials:
References:
Clinical trial NCT02120235: Investigating Lysosomal Storage Diseases in Minority Groups
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lysosomal Storage Disorders
Gaucher Disease
Fabry Disease
Pompe Disease
Niemann-Pick Disease
Keywords: Lysosomal storage disorders
LSD
Gaucher disease
Fabry disease
Pompe disease
Niemann-Pick disease
Lead sponsor: O & O Alpan LLC
Sponsor class: OTHER
First posted: 2014-04-22
Enrollment: 20000
Sex: ALL
Minimum age (years): 1
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area .

Brief summary: Although lysosomal storage disorders, such as Fabry disease, Gaucher disease, and Pompe disease, represent serious challenges in the healthcare system, no study has yet investigated the prevalence of these diseases in the US. Frequently, patients show progressive worsening of symptoms for several years before they get diagnosed. Since many of these diseases can be managed therapeutically, it is important to identify and treat patients in order to avoid organ damage. The investigators aim to undertake a screening study that identifies undiagnosed patients with lysosomal storage disorders and determine the prevalence of these diseases with special focus on underrepresented minority groups.


Eligibility criteria: Inclusion Criteria:

* Subject is greater than or equal to 1 day of age and less than or equal to 100 years of age
* Subject is managed by a physician in the Washington, D.C metro area
* Subject is getting blood work as part of standard clinical care and there is at least 60 uL blood remained in a tube after all clinical tests were run

Exclusion Criteria:

* Absolute contraindication for blood drawing
* Subject cannot be traced back by the referring physician upon a positive screening result

Primary outcomes:
measure: Number of patients identified with lysosomal storage disorders
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Fairfax
country: United States
facility: O&O Alpan, LLC
state: Virginia
Study officials:
References:
Clinical trial NCT06816758: Evaluation of Diagnosis and Treatment Methods in Corrosive Esophagitis: A 26-Year Experience-Based Algorithm
Official title: Evaluation of Diagnosis and Treatment Methods in Corrosive Esophagitis: Analysis of a 26-Year Experience-Based Algorithm
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Esophageal Diseases
Lead sponsor: Ondokuz Mayıs University
Sponsor class: OTHER
First posted: 2025-02-10
Enrollment: 501
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study focuses on patients diagnosed with corrosive esophagitis due to the ingestion of corrosive substances. The population includes individuals aged over 18 years who were hospitalized and treated at Ondokuz Mayıs University Thoracic Surgery Department between 1998 and 2024. The patients underwent clinical, laboratory, and radiological evaluations, and their outcomes were assessed retrospectively.

Brief summary: This study aims to evaluate the diagnosis and treatment methods for corrosive esophagitis based on 26 years of clinical experience. It will retrospectively analyze patient records to identify patterns in clinical outcomes, complications, and the effectiveness of treatment strategies. The study focuses on optimizing patient care by proposing a diagnosis and treatment algorithm that can guide future clinical practices. Data will be collected from hospital archives and electronic health records, covering cases of corrosive esophagitis managed at Ondokuz Mayıs University between 1998 and 2024.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with corrosive esophagitis due to corrosive substance ingestion.
* Hospitalized and treated at Ondokuz Mayıs University Thoracic Surgery Department.
* Patients who underwent clinical, laboratory, and radiological evaluations to confirm the diagnosis.
* Patients who were monitored and met follow-up criteria during their treatment.
* Patients above 18 years of age

Exclusion Criteria:

* Patients under 18 years of age.
* Patients who refused hospitalization or treatment.
* Patients who ingested non-corrosive or non-toxic substances (verified by the Ministry of Health Poison Information Center).
* Patients lost to follow-up or did not complete follow-up requirements.
* Patients with incomplete data during the diagnostic or treatment process.

Primary outcomes:
measure: Incidence of Esophageal Stricture, Perforation, and Other Related Complications
timeFrame: Within 1 month after hospital admission
Secondary outcomes:
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Ondokuz Mayıs University Faculty of Medicine
Study officials:
References:
Clinical trial NCT06678958: Outcomes of Trabecular Metal Augments Used in the Flying Buttress Position
Official title: Intermediate Term Outcomes of Trabecular Metal Augments Used in the Flying Buttress Position in the Management of Acetabular Defects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acetabular Abnormality
Keywords: Acetabular augments
Flying buttress
Revision total hip replacement
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-11-07
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study hypothesize that trabecular metal augments used in the flying buttress position is a valid option with good results in the management of uncontained acetabular defects.


Eligibility criteria: Inclusion Criteria:

* both sexes
* 18 years or older
* acetabular defect paprosky 2b or 3a segemntal defect reconstructed with trabecualr metal augment in the flying buttress position.

Exclusion Criteria:

* patients presented with active infection
* pathological defects
* pelvic discontinuity

Primary outcomes:
measure: Functionl hip status
timeFrame: 8 years
measure: Survivorship of the construct
timeFrame: 8years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: